In Vitro and In Vivo Potency of Moxifloxacin and Moxifloxacin Ophthalmic Solution 0.5%, A New Topical Fluoroquinolone

Stroman, David W.; Dajcs, Joseph J.; Cupp, G.; Schlech, Barry A.

doi:10.1016/j.survophthal.2005.06.002

Cited by 69 publications

(41 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other authors published that ocular S. epidermidis retrieved from conjunctivitis are clearly more susceptible to moxi- (19) . Fluoroquinolone antibiotics are concentration-dependent killers in that the MIC must be reached for the antibiotic to be effective.…”

Section: Discussionmentioning

confidence: 98%

Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection

Oliveira¹,

Hofling-Lima²,

Belfort³

et al. 2007

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection

Oliveira¹,

Hofling-Lima²,

Belfort³

et al. 2007

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

“…According to meta-analyses, moxifloxacin had more efficacy and lower drop-out rates compared to ofloxacin or polymyxin/trimethoprim [43,44]. Furthermore, moxifloxacin also covers anaerobic bacteria, superior to activity observed with gatifloxacin [45]. Besifloxacin ophthalmic suspension, the latest chloro-fluoroquinolone approved for treating bacterial conjunctivitis, has demonstrated clinical efficacy and safety in treatment of adult patients with culture-confirmed acute bacterial conjunctivitis from both aerobic and anaerobic infection [46,47].…”

Section: Bacterial Conjunctivitismentioning

confidence: 99%

Conjunctivitis: Systematic Approach to Diagnosis and Therapy

Thanathanee

O’Brien

2011

Curr Infect Dis Rep

View full text Add to dashboard Cite

Conjunctivitis is a common problem in primary health care. Inflammation of the conjunctiva may result from infection or noninfectious causes. Microbial conjunctivitis may be caused by bacteria, viruses, or parasites. Although usually a benign, self-limited disease in healthy individuals, serious complications (eg, keratitis) may be sight-threatening. Accurate diagnosis and specific treatment of conjunctivitis remain challenging. History taking and physical examination are occasionally insufficient for correct diagnosis, thus laboratory testing may play a vital role in identification of specific pathogen(s). However, diagnostic testing has several limitations, including time-consuming methods, increased cost, and requirement for expertise in performance and interpretation. Treatment with empirical topical antibiotics for suspected infectious conjunctivitis is controversial. Although antibiotic treatment can diminish risk of adverse events and shorten the course of disease, drug resistance, toxicity, and expense are important considerations in management of acute infectious conjunctivitis.

show abstract

“…Fourth-generation quinolones are important drugs used in ophthalmology and are more effective against Gram-positive bacteria compared to the other generations (Scoper, 2008;Stroman et al, 2005). This generation has also been demonstrated to be more active against mycobacteria and less affected by mutations in DNA gyrase .…”

Section: Introductionmentioning

confidence: 99%

Phenotypic and molecular characterization of quinolone resistance in Mycobacterium abscessus subsp. bolletii recovered from postsurgical infections

Moura

Silva

Gomes

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

Several outbreaks of infections caused by rapidly growing mycobacteria (RGM) were reported in many Brazilian states (2032 notified cases) from 2004 to 2010. Most of the confirmed cases were mainly associated with Mycobacterium massiliense (recently renamed as Mycobacterium abscessus subsp. bolletii) BRA100 clone, recovered from patients who had undergone invasive procedures in which medical instruments had not been properly sterilized and/or disinfected. Since quinolones have been an option for the treatment of general RGM infections and have been suggested for therapeutic schemes for these outbreaks, we evaluated the in vitro activities of all generations of quinolones for clinical and reference RGM by broth microdilution, and analysed the peptide sequences of the quinolone resistance determining regions (QRDRs) of GyrA and GyrB after DNA sequencing followed by amino acid translation. Fifty-four isolates of M. abscessus subsp. bolletii, including clone BRA100, recovered in different states of Brazil, and 19 reference strains of RGM species were characterized. All 54 M. abscessus subsp. bolletii isolates were resistant to all generations of quinolones and showed the same amino acids in the QRDRs, including the Ala-83 in GyrA, and Arg-447 and Asp-464 in GyrB, described as being responsible for an intrinsic low level of resistance to quinolones in mycobacteria. However, other RGM species showed distinct susceptibilities to this class of antimicrobials and patterns of mutations contrary to what has been traditionally defined, suggesting that other mechanisms of resistance, different from gyrA or gyrB mutations, may also be involved in resistance to high levels of quinolones.

show abstract

In Vitro and In Vivo Potency of Moxifloxacin and Moxifloxacin Ophthalmic Solution 0.5%, A New Topical Fluoroquinolone

Cited by 69 publications

References 116 publications

Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection

Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection

Conjunctivitis: Systematic Approach to Diagnosis and Therapy

Phenotypic and molecular characterization of quinolone resistance in Mycobacterium abscessus subsp. bolletii recovered from postsurgical infections

Contact Info

Product

Resources

About